New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
06:35 EDTBAX
theflyonthewall.com: Baxter initiated with a Market Perform at Morgan Keegan
:theflyonthewall.com



News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
There are 7 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2010
08:39 EDTBAX
theflyonthewall.com: Edwards Lifesciences' new heart valve is less intrusive, IBD reports

Subscribe for More Information
:theflyonthewall.com

January 28, 2010
09:59 EDTBAX
theflyonthewall.com: Baxter weakness a buying opportunity, says Piper Jaffray

Subscribe for More Information
:theflyonthewall.com
07:26 EDTBAX
theflyonthewall.com: Baxter sees Q1 EPS 92c-94c vs. consensus of 95c
Sees Q1 revenue up 5%-7%. :theflyonthewall.com
07:25 EDTBAX
theflyonthewall.com: Baxter sees FY10 EPS $4.20-$4.28 vs. consensus of $4.28

Subscribe for More Information
:theflyonthewall.com
07:23 EDTBAX
theflyonthewall.com: Baxter reports Q4 EPS $1.03 vs. consensus of $1.03
Reports Q4 $3.5B vs. consensus of $3.39B. :theflyonthewall.com

January 27, 2010
12:12 EDTBAX
theflyonthewall.com: Earnings Preview: Baxter's Q4 may hinge on IVIG supply, demand status
Baxter International (BAX) is expected to report Q4 earnings before the market open on Thursday, January 28, with a conference call scheduled for 8:30am ET. The consensus estimate is $1.03 for EPS and $3.38B for revenue, according to First Call. On October 15, Baxter reaffirmed its Q4 EPS guidance of $1.02 to $1.04 vs. consensus of $1.04 on sales growth of 7% to 8%. On its Q3 conference call the company said it sees strong demand and pricing across its plasma protein portfolio. Another positive for its Q4 results may be the fact that the company did not recognize H1N1 vaccine revenue in Q3. Possible negatives for this quarter could come from a shift in demand for intravenous immunolglobulin or IVIG for 2010. On December 4, Soleil Securities said it's "nervous" about intravenous immunolglobulin or IVIG, supply, demand fundamentals heading into 2010. The firm said IVIG levels are moving higher and has negative implications for Baxter (BAX) and Talecris Bio (TLCR). On January 27, Piper Jaffray mentioned Baxter positively ahead of Q4 results. Piper thinks investors will view Baxter's Q4 results and 2010 guidance positively, and would be a buyer of the stock ahead of the report. The firm maintains an Overweight rating on the stock. :theflyonthewall.com
08:20 EDTBAX
theflyonthewall.com: Baxter mentioned positively ahead of results at Piper Jaffray

Subscribe for More Information
:theflyonthewall.com